PRNewsWire
12 Feb 2026, 23:56 UTC · 34w ago
Verdict
Headline takes no side. We score VNDA −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA concluded that Vanda's sNDA for HETLIOZ® for jet lag disorder cannot be approved in its current form, finding clinical trial data do not provide substantial evidence of effectiveness for this indication.
More negative than 99% of claims this week
Vanda's stock price fell 14.05% on January 8, 2026, following the announcement of the FDA's decision on HETLIOZ®.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
Pomerantz LLP is investigating claims on behalf of Vanda investors concerning whether the company and certain officers or directors engaged in securities fraud or other unlawful business practices.
More negative than 85% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company received an FDA rejection for its jet lag treatment and is facing a securities fraud investigation.
More negative than 84% of ticker scores this week
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
More negative than 84% of ticker scores this week
The company is the subject of an investigation by Pomerantz LLP on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
−31.0%
Price agrees with the score
$4.22 vs $6.12 close before publication (Feb 12) · not market-adjusted
VNDA chart →
